Ocular Therapeutix Inc (OCUL)

6.83 +0.07 (+1.04%) USD  |  NASDAQ  |  Jun 28, 16:00
6.80 -0.03 (-0.44%) After-Hours: 20:00
More

Ocular Therapeutix Research and Development Expense (TTM): 67.04M for March 31, 2024

Research and Development Expense (TTM) Chart

Historical Research and Development Expense (TTM) Data

View and export this data back to 2013. Upgrade now.
Date Value
March 31, 2024 67.04M
December 31, 2023 61.06M
September 30, 2023 58.40M
June 30, 2023 57.10M
March 31, 2023 55.11M
December 31, 2022 53.46M
September 30, 2022 52.50M
June 30, 2022 51.50M
March 31, 2022 52.26M
December 31, 2021 50.08M
September 30, 2021 45.13M
June 30, 2021 39.36M
March 31, 2021 33.52M
December 31, 2020 28.69M
September 30, 2020 31.20M
June 30, 2020 34.48M
March 31, 2020 35.87M
December 31, 2019 41.09M
September 30, 2019 41.22M
June 30, 2019 40.67M
March 31, 2019 40.00M
Date Value
December 31, 2018 36.92M
September 30, 2018 34.56M
June 30, 2018 33.01M
March 31, 2018 32.38M
December 31, 2017 30.88M
September 30, 2017 30.30M
June 30, 2017 27.86M
March 31, 2017 26.72M
December 31, 2016 27.06M
September 30, 2016 26.62M
June 30, 2016 29.20M
March 31, 2016 28.96M
December 31, 2015 26.61M
September 30, 2015 24.87M
June 30, 2015 21.09M
March 31, 2015 18.64M
December 31, 2014 18.88M
September 30, 2014 16.57M
June 30, 2014 14.88M
March 31, 2014 12.99M
December 31, 2013 10.52M

R&D Expense Definition

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (TTM) Range, Past 5 Years

28.69M
Minimum
Dec 2020
67.04M
Maximum
Mar 2024
46.49M
Average
47.61M
Median

Research and Development Expense (TTM) Benchmarks

Amgen Inc 5.069B
EyePoint Pharmaceuticals Inc 81.18M
Regeneron Pharmaceuticals Inc 4.586B
Agios Pharmaceuticals Inc 296.84M
Fate Therapeutics Inc 139.10M